medigraphic.com

2020, Number 2

<< Back Next >>

Rev Hematol Mex 2020; 21 (2)

Cytogenetics characteristics of adults with myelodysplastic syndromes according to WHO classification criteria

Rozo-Agudelo PA, Jaramillo-Arbelaez PE

Language: Spanish
References: 46
Page: 103-114
PDF size: 348.43 Kb.


ABSTRACT

Background: Myelodysplastic syndromes are a group of heterogeneous hematologic alterations; the investigations carried out that describe the cytogenetic alterations show discrepancies that do not allow to have a complete profile.
Objective: To identify the cytogenetic characteristics related to myelodysplastic syndromes according to WHO classification criteria.
Method: A systematic review of the literature published in databases was done from January 2-10, 2018. The research protocol was applied, as well as a quality assessment according to the STROBE guideline.
Results: During the screening phase, 141,924 articles were obtained, of which 11 fulfilled the research protocol for qualitative synthesis. The analysis by geographic regions found a higher prevalence of male patients, except in Brazil where the female population predominated over the males. The average age also varied; the Asian population has an average age of 56.6, while the rest of the world was above 60 years. The proportion of cytogenetic alterations varied according to the WHO classification and geographic region; in America the most frequent was (5q), in Europe the deletions (5q) and (20q), and in Asia the trisomy 8.
Conclusions: This review made it possible to visualize the difference in the cytogenetic characteristics of myelodysplastic syndromes with WHO classification depending on the geographical region and complexity of the disease.


REFERENCES

  1. Arber DA, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-2405. DOI: 10.1182/blood-2016-03-643544.

  2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302. DOI: 10.1182/ blood-2002-04-1199.

  3. Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN. Wintrobe’s clinical hematology. 13 ed. Philadelphia: Lippincott Williams & Wilkins, 2014;1543-1555.

  4. Bennett JM, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189- 199.

  5. Mufti GJ, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus pro posals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 2008;93:1712-7. DOI: 10.3324/haematol.13405.

  6. Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica 2013;98:568-75. DOI: 10.3324/haematol.2012.071449.

  7. Xiaomei M. Epidemology of myelodysplastic syndromes. Am J Med 2012;125:S2-5. doi: 10.1016/j.amjmed. 2012.04.014.

  8. Carvalhosa A, Killick SB. Myelodysplastic disorders. Medicine (Baltimore) 2017;45:270-274. DOI:https://doi. org/10.1016/j.mpmed.2017.02.006.

  9. Goldberg SL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010;28:2847-2852. DOI: 10.1200/JCO.2009.25.2395.

  10. Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: High number of uncaptured cases by cancer registries. Blood 2011;117:7121-7125. DOI: https://dx.doi. org/10.1182%2Fblood-2011-02-337964.

  11. Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am 2010;24:287-294. DOI: 10.1016/j.hoc.2010.02.011.

  12. Deeg HJ, et al. Myelodysplastic syndromes. 2nd ed. USA: Springer, 2013;41-45.

  13. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008;35:418-429. https://dx.doi. org/10.1053%2Fj.seminoncol.2008.04.012.

  14. Narayanan S. Clinical, hematological, and cytogenetic profile of adult myelodysplastic syndrome in a tertiary care center. J Blood Med 2017;8:21-27. DOI: 10.2147/JBM.S129111.

  15. Zagozdzon R, Golab J. Cancer stem cells in haematological malignancies. Contemp Oncol 2015;19:A1-6. doi: 10.5114/ wo.2014.47127.

  16. Alves A de SBM, Bataglia FB, Conterno L de O, Segato R, Payão SLM. Epidemiological and cytogenetic profiles of patients with hematological malignancies and their relationship with aging. Hematol Transfus Cell Ther 2018;40:200-206. doi: 10.1016/j.htct.2017.10.001.

  17. Bacher U, Kern W, Alpermann T, Schnittger S, Haferlach C, Haferlach T. Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Leuk Res 2012;36:826- 831. DOI: 10.1016/j.leukres.2012.04.003.

  18. Martinez J, Lucía M. Análisis cromosómico por medio de técnicas citogenéticas clásicas y moleculares en un grupo de pacientes con síndrome mielodisplásico y leucemia mieloide aguda del Instituto Nacional de Cancerología. Colombia, Universidad Nacional de Colombia, 2015;42-51.

  19. Hofmann WK, Nolte F. Molecular targets in myelodysplastic syndromes. Cancer Treat 2007;33:S42-S46. https://doi. org/10.1016/j.ctrv.2007.07.015.

  20. Groupe Français de Cytogénétique Hématologique. Cytogenetics of chronic myelomonocytic leukemia. Cancer Genet Cytogenet 1986;30:11-30. DOI: 10.1038/bcj.2016.5.

  21. Haase D, et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol 1995;70:171-187.

  22. Haase D, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007;110:4385- 4395. DOI: 10.1182/blood-2007-03-082404.

  23. Solé F, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000;108:346-356. DOI: 10.1046/j.1365- 2141.2000.01868.x.

  24. Le Beau MM, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no 5 and 7. J Clin Oncol 1986;4:325-345. DOI: 10.1200/JCO.1986.4.3.325.

  25. Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465. DOI: 10.1182/ blood-2012-03-420489.

  26. Shumilov E, et al. Current status and trends in the diagnostics of AML and MDS. Blood Rev 2018;32:508-519. DOI: 10.1016/j.blre.2018.04.008.

  27. Byun JM, et al. Cytogenetic profiles of 2806 patients with acute myeloid leukemia a retrospective multicenter nationwide study. Ann Hematol 2016;95:1223-1232. DOI: 10.1007/s00277-016-2691-1.

  28. Wang H, Wang X, Xu X, Lin G. Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: A multicenter study. Ann Hematol 2010;89:535- 544. DOI: 10.1007/s00277-009-0861-0.

  29. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-32. DOI: 10.1182/blood-2011-01-293050.

  30. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. DOI: 10.1371/journal.pmed.1000097.

  31. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg 2014;12:1495-9. DOI: 10.1016/j.jclinepi.2007.11.008.

  32. Zhang T, et al. Monosomal karyotype of chromosome 5/7 was an independent poor prognostic factor for Chinese myelodysplastic syndrome patients. Cancer Genet 2016;209:423-429. DOI: 10.1016/j.cancergen.2016.06.007.

  33. Gangat N, et al. Primary myelodysplastic syndromes: The Mayo Clinic experience with 1000 patients. Mayo Clin Proc 2015;90:1623-1638. DOI: 10.1016/j.mayocp.2015.08.022.

  34. Sánchez-Castro J, et al. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. Leuk Res 2013;37:769- 776. DOI: 10.1016/j.leukres.2013.04.010.

  35. Dambruoso I, et al. Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome. Cancer Genet 2012;205:285-294. DOI: 10.1016/j.cancergen.2012.03.004.

  36. Lee HR, et al. Cytogenetic features of 5q deletion and 5q− syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization. Cancer Genet Cytogenet 2010;203:193-202. DOI: 10.1016/j.cancergencyto. 2010.08.007.

  37. Jung SW, et al. Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution. Leuk Res 2011;35:735-740. DOI: 10.1016/j.leukres.2010.11.009.

  38. Wang H, Wang XQ, Xu XP, Lin GW. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome. Cancer Genet Cytogenet 2010;196:159-166. DOI: 10.1016/j.cancergencyto.2009.09.015.

  39. Costa D, et al. Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do? Leuk Res 2010;34:1437-1441. DOI: 10.1016/j. leukres.2010.02.019.

  40. Li L, et al. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. Leuk Res 2009;33:1194-1198. DOI: 10.1016/j.leukres.2008.11.021.

  41. Liu Y-C, et al. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 2006;171:9-16. DOI: 10.1016/j.cancergencyto. 2006.06.003.

  42. Romeo M, Chauffaille Mde L, Silva MR, Bahia DM, Kerbauy J. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leuk Res 2002; 26:993-996. DOI: 10.1016/s0145-2126(02)00047-4.

  43. Stölzel F, et al. Karyotype complexity and prognosis in acute myeloid leukemia. Blood Cancer J 2016;6:e386. DOI: 10.1038/bcj.2015.114.

  44. Stone JF, Sandberg AA. Sex chromosome aneuploidy and aging. Mutat Res 1995;338:107-113. DOI: 10.1016/0921- 8734(95)00016-y.

  45. Shay JW. Role of telomeres and telomerase in aging and cancer. Cancer Discov 2016;6:584-93. ฀ DOI: 10.1158/2159- 8290.CD-16-0062.

  46. Nomdedeu M, et al. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leuk Res 2017;63:85-89. DOI: 10.1016/j.leukres.2017.10.011.




2020     |     www.medigraphic.com